↓ Skip to main content

Dove Medical Press

Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis

Overview of attention for article published in Drug Design, Development and Therapy, August 2011
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

policy
1 policy source

Citations

dimensions_citation
51 Dimensions

Readers on

mendeley
53 Mendeley
Title
Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis
Published in
Drug Design, Development and Therapy, August 2011
DOI 10.2147/dddt.s14018
Pubmed ID
Authors

Jennifer A Dickens, David A Lomas

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 6%
Germany 1 2%
Colombia 1 2%
United Kingdom 1 2%
Australia 1 2%
Unknown 46 87%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 19%
Student > Master 10 19%
Student > Ph. D. Student 9 17%
Student > Bachelor 5 9%
Other 4 8%
Other 8 15%
Unknown 7 13%
Readers by discipline Count As %
Medicine and Dentistry 19 36%
Agricultural and Biological Sciences 16 30%
Biochemistry, Genetics and Molecular Biology 5 9%
Neuroscience 2 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 2 4%
Unknown 8 15%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 December 2017.
All research outputs
#8,551,190
of 25,411,814 outputs
Outputs from Drug Design, Development and Therapy
#643
of 2,271 outputs
Outputs of similar age
#46,705
of 130,368 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 1 outputs
Altmetric has tracked 25,411,814 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,271 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 130,368 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them